Replies to post #158189 on Biotech Values

[DonShimoda]

XOMA’s 12/31/12 cash balance=$85M; expected 2013 cash burn=$50M

XOMA is fully funded through the end of 2014 and all three Ph3 Eyeguard read-outs. However by the time the Eyeguard-A data is available, the company will have ~ 12mo runway. If Eyeguard-A data is positive, I suspect they'll use the opportunity to raise $'s in front of what would then be the pivotal Eyeguard-C data.